Status:
UNKNOWN
Generation Of a Lung Biobank for Future Use
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The aim is to invite 1,000 patients with symptoms triggering the lung cancer diagnostic pathway or with significant risks of lung cancer, referred to The Royal Marsden NHS Foundation Trust (RMH) refer...
Detailed Description
Patients will have been referred under the two week rule (TWR) diagnostic pathway, some will have lung cancer, others not, and other patients will have had a diagnosis of lung cancer by other pathways...
Eligibility Criteria
Inclusion
- One of the following criteria:
- Patients with lung cancer at any stage or time in their disease.
- Patients without lung cancer who have been referred by the TWR pathway.
- Patients without lung cancer who have radiological changes on their X-Ray or CT scan that need follow up.
- Patients without lung cancer who have a strong family history of lung cancer. PLUS
- Patients aged \>18 Years
- Patients who have signed informed consent form
Exclusion
- Unable to provide informed consent.
- Bleeding disorder or other medical condition that would make a blood sample hazardous.
- Within 3 weeks of chemotherapy or radiotherapy (as low lymphocyte may be associated with poor DNA yield).
Key Trial Info
Start Date :
October 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05234138
Start Date
October 31 2019
End Date
October 31 2023
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden Hospital NHS Foundation Trust
London, United Kingdom, SW3 6JJ